Four Weeks of Treatment With Rifaximin Fails to Significantly Alter Microbial Diversity in Rectal Samples of HIV-Infected Immune Non-Responders (ACTG A5286) Which May be Attributed to Rectal Swab Use.

ABSTRACT:

Introduction

HIV-infected individuals have evidence of intestinal microbial translocation which is associated with immune activation and unfavorable clinical outcomes. Rifaximin, a non-absorbable antibiotic which reduces microbial translocation in other disease states, was shown to have a marginal beneficial effect on microbial translocation, T-cell activation, and inflammation in a multisite randomized trial (ACTG A5286; NCT01466595) of HIV-infected persons with poor immunologic recovery receiving ART. Here, we report analysis of the rectal microbiome changes associated with that trial.

Methods

HIV-1-infected individuals receiving ART with CD4-T cell count < 350cells/mm³ and viral suppression were randomized 2:1 to rifaximin or no therapy for 4 weeks. Rectal swab

SUBMITTER: Williams BB 

PROVIDER: S-EPMC6768152 | biostudies-literature | 2019

REPOSITORIES: biostudies-literature